Blogs

A lentiviral vector CDMO is a specialized partner that develops, manufactures, and tests lentiviral vectors under GMP-ready quality systems so cell therapy companies can move from discovery into IND/C...

Suspension and adherent lentivirus production are two proven manufacturing approaches, and CDMOs choose between them based on your required dose demand, timeline, cost targets, facility fit, and the r...

The pharmaceutical industry is a complex ecosystem that involves various players and processes aimed at delivering safe and effective treatments to patients worldwide. One of these key players is the ...

The rapid advancement in biomedical research has propelled cell therapy products into the limelight as a novel solution for a variety of medical conditions. These innovative interventions have shown p...

Cell therapy products are revolutionizing the medical sector by offering innovative treatments for a variety of diseases and conditions. At its core, cellular therapy leverages the body's own cell...

Cell therapy is a rapidly evolving field in medicine that is revolutionizing treatment approaches for a myriad of diseases. By utilizing living cells as therapeutic agents, cell therapy presents a pro...

The realm of modern medicine is continually evolving, introducing cutting-edge treatments like cell therapy products that offer new hope for a wide range of medical conditions. As the demand for perso...

What we know about the safety, efficacy of mRNA vaccines amid recent scrutinyOver the last several days, the safety and efficacy of messenger RNA, or mRNA, vaccines have come under intense scrutiny.On...

Estimate IFU for MOI accuracy; use functional titration, optimize vectors, transfection, and enhancers to boost lentiviral efficiency.

The NRC developed Canada’s first nanobody-based CAR T-cell therapy targeting CD22, offering a precise, innovative treatment for blood cancers with potential for broader applications.

Choose cell health assays based on your model, marker type, culture system, and timing needs; multiplex for richer, reliable data.

IL-2 is vital for expanding TILs, CAR-T, and NK cells in cancer immunotherapy, though toxicity concerns are driving innovations like orthogonal IL-2 systems and cytokine combinations for safer, effective treatment.